Aclaris Therapeutics Stock Probability of Future Stock Price Finishing Over 1.22
| ACRS Stock | USD 2.60 0.12 4.84% |
Aclaris |
Aclaris Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aclaris Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aclaris Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Aclaris Therapeutics is way too risky over 90 days horizon | |
| Aclaris Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 31.25 M. Net Loss for the year was (88.48 M) with loss before overhead, payroll, taxes, and interest of (60.02 M). | |
| Aclaris Therapeutics currently holds about 248.6 M in cash with (78.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 90.0% of the company shares are held by institutions such as insurance companies |
Aclaris Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aclaris Stock often depends not only on the future outlook of the current and potential Aclaris Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aclaris Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 69.8 M | |
| Cash And Short Term Investments | 119.1 M |
Aclaris Therapeutics Technical Analysis
Aclaris Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Aclaris Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Aclaris Therapeutics. In general, you should focus on analyzing Aclaris Stock price patterns and their correlations with different microeconomic environments and drivers.
Aclaris Therapeutics Predictive Forecast Models
Aclaris Therapeutics' time-series forecasting models is one of many Aclaris Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Aclaris Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Aclaris Therapeutics
Checking the ongoing alerts about Aclaris Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Aclaris Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Aclaris Therapeutics is way too risky over 90 days horizon | |
| Aclaris Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 31.25 M. Net Loss for the year was (88.48 M) with loss before overhead, payroll, taxes, and interest of (60.02 M). | |
| Aclaris Therapeutics currently holds about 248.6 M in cash with (78.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 90.0% of the company shares are held by institutions such as insurance companies |
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.